Author(s):
Sonia Sharma, Dinesh Prasad Yadav, Balvinder Singh, Ram Charan Chhipa
Email(s):
rishisonia1613@gmail.com
DOI:
Not Available
Address:
Sonia Sharma1*, Dinesh Prasad Yadav2, Balvinder Singh3, Ram Charan Chhipa2
1Dept. of Microbiology, JN Medical College, Belgaum (KA).
2Dept. of Biochemistry, Suresh Gyan Vihar University, Mahal Jagatpura, Jaipur (RJ).
3Swami Vivekananda Mahavidhyalay, Sahajahanpur (UP).
*Corresponding Author
Published In:
Volume - 5,
Issue - 10,
Year - 2012
ABSTRACT:
Extraction of different parts of medicinal plants are used as a medicine, about 80% of the world population rely on plant derived medicines to cope their health care needs. Ethnobotany deals with the relationship between humans and plants in all its sophisticated issues. One of the most common problems regarding the existing gap between the traditional practice and modern medicine is scientifically unjustified use of plants in treatment for different type of infectious disease in various parts of the world including India. This experimental study was focused on the justification of botanical description, antimicrobial activity screening and determination of minimum inhibitory concentration (MIC) of plants traditionally used as a treatment of various bacterial and fungal diseases. Traditionally used medicinal plant namely Plumbago zeylanica (Plumbaginaceae), extracted by soxhlet extraction method was screened for antimicrobial activity against Escherichia coli , Staphylococcus aureus and Candida albicans, which showed better antimicrobial activity in the initial screening test, were selected for secondary screening at 100 mg/ml and 50 mg/ml.
Cite this article:
Sonia Sharma, Dinesh Prasad Yadav, Balvinder Singh, Ram Charan Chhipa. Antimicrobial activity of the Soxhlet extraction of Plumbago zeylanica leaf extracts In-vitro conditions. Research J. Pharm. and Tech. 5(10): October 2012; Page 1297-1300.
Cite(Electronic):
Sonia Sharma, Dinesh Prasad Yadav, Balvinder Singh, Ram Charan Chhipa. Antimicrobial activity of the Soxhlet extraction of Plumbago zeylanica leaf extracts In-vitro conditions. Research J. Pharm. and Tech. 5(10): October 2012; Page 1297-1300. Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2012-5-10-3
REFERENCES:
1. Grabley S, Thiericke R. Drug discovery from nature. Spinger, Berlin, Heidelberg, London 1999.
2. Evans CE, Banso A, Samuel OA. Efficacy of some nupe medicinal plants against Salmonella typhi: an in vitro study. J. Ethnopharmacol. 80; 2002: 21-24.
3. Saxena K. Antimicrobial screening of selected medicinal plants from India. J. Ethnopharmacol. 58; 1997: 75-83.
4. Nimri LF, Meqdam MM, Alkofahi A. Antibacterial activity of Jordanian medicinal plants. Pharmacol. Biol. 3; 1999: 196-201.
5. Saxena VK, Sharma RN. Antimicrobial activity of essential oil of Lankana aculeata. Fitoterapia. 70; 1999: 59-60.
6. Chang HW. Antibacterial effect of spices and vegetables, Food Ind. (Roc).27; 1995: 53-61.
7. Mitscher LA, Drake S, Golloapudi SR, Okwute SK . A modern look at folkloric use of antiinfective agents. J. Nat. Prod. 50; 1987: 1025- 1040.
8. Eloff JN. Which extract and should be used for the screening and isolation of antimicrobial components from plants. J. Ethnopharmacol. 60; 1988: 1-8.
9. Hammer KA, Carson CF, Riley TV. Antimicrobial activity of essential oils and other plant extracts. J. Appl. Microbiol. 86; 1999: 985- 990.
10. Devi, Sudha Devi M. and Thenmozhi M. Antibacterial Activity of Plumbago zeylanica Leaf Extract. International Journal of Research in Biomedicine and Biotechnology 1.1 (2011):1-4.Universal Research Publications. Web. 31 Mar. 2012. URL: http://urpjournals.com/tocjnls/28_1.pdf>.
11. Zakaria M. Isolation and characterization of active compounds from medicinal plants. Asia Pacific Journal of Pharmacology. 6; 1991: 15-20.
12. Sokmen A. Jones BM. Erturk M. The in vitro antibacterial activity of Turkish medicinal plants. Journal of Ethnopharmacology. 67 (1); 1999: 79-86.
13. Collins CH, Lyne PM, Grange JM (1995). Microbiological Methods. Seventh ed., Butterworths, London.
14. Collins CH. Lyne PM. Grange JM. Microbiological Methods. Seventh ed., Butterworths, London, 1995
15. Nurdan Sarac and Aysel Ugur. Antimicrobial activities and usage in folkloric medicine of some Lamiaceae species growing in Mugla, Turkey. EurAsian Journal of BioSciences. 4; 2007: 28-37.
16. Gupta RS. Protein phylogenies and signature sequences: A reappraisal of evolutionary relationships among archaebacteria, eubacteria and eukaryotes. Microbiol. Mol. Biol. Rev. 62; 1998: 1435-1491.
17. Gupta RS. What are archaebacteria: life’s third domain or monoderm prokaryotes related to Gram-positive bacteria? A new proposal for the classification of prokaryotic organisms. Molecular Microbiology. 29(3); 1998: 695-707.
18. Todd JK. Toxic shock syndrome. Clinical Microbiology Reviews. 1; 1998: 432-446.
19. Hajjeh RA. Reingold A. Weil A. Shutt K. Schuchat A.Perkins BA. Toxic shock syndrome in the United States: surveillance update, 1979-1996. Emerging Infectious Diseases. 5; 1999: 807- 810.
20. Rubin RJ. Harrington CA. Poon A. Dietrich K. Grene JA. Moiduddin A. The economic impact of Staphylococcus infection in New York City hospitals. Emerging Infectious Diseases. 5; 1999: 9-17.
21. Al-Masaudi SB. Day MJ. Russell AD. Antimicrobial resistance and gene transfer in Staphylococcus aureus. Journal of Applied Bacteriology. 70; 1991: 270-290.
22. Kloos WE. Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR. Baron EJ. Pfaller MA. Tenover FC. Yolken RH. Manual of clinical microbiology. D.C. Washington, 1995; 6th ed. pp.282-298.
23. Hiramatsu K. Hanaki H. Ino T. Yabuta K. Oguri T. Tenover FC. Methicillin- resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy. 40; 1997: 135-136.
24. Noble WC. Virani Z. Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letters 93; 1992: 195-198.
25. Huycke MM. Sahm DF. Gilmore MS. Multiple drug resistant enterococci: the nature of the problem and an agenda for the future. Emerging Infectious Diseases 4; 1998: 239-249.